순번 | 임상시험 제목 | 적응증 | 연구설계 | 의뢰자/실시기관 | 임상단계 | NCT No | 개시일자 |
---|---|---|---|---|---|---|---|
1 | Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn's Disease | Perianal Fistula Due to Crohn's Disease|Fistula in Ano | Biological: Human umbilical cord mesenchymal stem cells (UC-MSCs) | CryoCord Sdn Bhd|University of Malaya | Phase 1 | NCT05039411 | 2022-03-01 |
2 | Immunotherapy for Advanced Liver Cancer | Hepatocellular Carcinoma | Biological: AlloStim짰 immunotherapy|Drug: FOLFOX regimen|Other: Best Supportive Care | Immunovative Therapies, Ltd.|Mirror Biologics, Inc. | Phase 2|Phase 3 | NCT05033522 | 2022-02-01 |
3 | MK-1654 in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) | RSV Infection | Biological: MK-1654|Biological: Palivizumab|Biological: Placebo | Merck Sharp & Dohme LLC | Phase 3 | NCT04938830 | 2021-11-30 |
4 | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure | Carcinoma, Non-Small-Cell Lung | Drug: Lazertinib|Drug: Amivantamab|Drug: Pemetrexed|Drug: Carboplatin | Janssen Research & Development, LLC | Phase 3 | NCT04988295 | 2021-11-17 |
5 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | Colorectal Cancer | Biological: favezelimab/pembrolizumab|Drug: regorafenib|Drug: TAS-102 | Merck Sharp & Dohme LLC | Phase 3 | NCT05064059 | 2021-11-10 |
6 | Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study | COVID-19 Pandemic | Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|Biological: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) | Livzon Pharmaceutical Group Inc. | Phase 3 | NCT05096832 | 2021-11-03 |
7 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | Arthritis, Psoriatic | Drug: Guselkumab|Drug: Placebo | Janssen Research & Development, LLC | Phase 3 | NCT04936308 | 2021-09-28 |
8 | Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents | COVID-19 | Biological: Inactivated COVID-19 Vaccine|Biological: Controlled vaccine | Sinovac Research and Development Co., Ltd.|Sinovac Biotech Co., Ltd | Phase 3 | NCT04992260 | 2021-09-10 |
9 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | Breast Neoplasms | Biological: pembrolizumab|Drug: paclitaxel|Drug: nab-paclitaxel|Drug: liposomal doxorubicin|Drug: capecitabine|Drug: normal saline|Drug: dextrose | Merck Sharp & Dohme LLC | Phase 3 | NCT04895358 | 2021-06-18 |
10 | Atacicept in Subjects With IgA Nephropathy | IgA Nephropathy|Berger Disease | Biological: Atacicept|Other: Placebo to match Atacicept | Vera Therapeutics, Inc. | Phase 2 | NCT04716231 | 2021-05-18 |